| Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion RD Leone, L Zhao, JM Englert, IM Sun, MH Oh, IH Sun, ML Arwood, ... Science 366 (6468), 1013-1021, 2019 | 861 | 2019 |
| Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells MH Oh, IH Sun, L Zhao, RD Leone, IM Sun, W Xu, SL Collins, AJ Tam, ... The Journal of clinical investigation 130 (7), 3865-3884, 2020 | 303 | 2020 |
| Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors K Shukla, DV Ferraris, AG Thomas, M Stathis, B Duvall, G Delahanty, J Alt, ... Journal of medicinal chemistry 55 (23), 10551-10563, 2012 | 238 | 2012 |
| Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer A Elgogary, Q Xu, B Poore, J Alt, SC Zimmermann, L Zhao, J Fu, B Chen, ... Proceedings of the National Academy of Sciences 113 (36), E5328-E5336, 2016 | 229 | 2016 |
| We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine KM Lemberg, JJ Vornov, R Rais, BS Slusher Molecular cancer therapeutics 17 (9), 1824-1832, 2018 | 185 | 2018 |
| Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma R Rais, A Jancarik, L Tenora, M Nedelcovych, J Alt, J Englert, C Rojas, ... Journal of medicinal chemistry 59 (18), 8621-8633, 2016 | 125 | 2016 |
| Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV JM Coughlin, Y Wang, S Ma, C Yue, PK Kim, AV Adams, HV Roosa, ... Journal of neurovirology 20, 219-232, 2014 | 102 | 2014 |
| Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo A Ghosh, L Li, L Xu, RP Dash, N Gupta, J Lam, Q Jin, V Akshintala, ... Science advances 6 (44), eabb4133, 2020 | 100 | 2020 |
| Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis KA Rahn, CC Watkins, J Alt, R Rais, M Stathis, I Grishkan, CM Crainiceau, ... Proceedings of the National Academy of Sciences 109 (49), 20101-20106, 2012 | 99 | 2012 |
| Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid … V Kumar, A Bonifazi, MP Ellenberger, TM Keck, E Pommier, R Rais, ... Journal of medicinal chemistry 59 (16), 7634-7650, 2016 | 97 | 2016 |
| Clinical development of metabolic inhibitors for oncology KM Lemberg, SS Gori, T Tsukamoto, R Rais, BS Slusher The Journal of clinical investigation 132 (1), 2022 | 92 | 2022 |
| Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects ZB You, GH Bi, E Galaj, V Kumar, J Cao, A Gadiano, R Rais, BS Slusher, ... Neuropsychopharmacology 44 (8), 1415-1424, 2019 | 84 | 2019 |
| N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated … MT Nedelcovych, L Tenora, BH Kim, J Kelschenbach, W Chao, E Hadas, ... Journal of medicinal chemistry 60 (16), 7186-7198, 2017 | 71 | 2017 |
| Novel and high affinity 2-[(diphenylmethyl) sulfinyl] acetamide (modafinil) analogues as atypical dopamine transporter inhibitors J Cao, RD Slack, OM Bakare, C Burzynski, R Rais, BS Slusher, T Kopajtic, ... Journal of medicinal chemistry 59 (23), 10676-10691, 2016 | 71 | 2016 |
| The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents CJ Jordan, B Humburg, M Rice, GH Bi, ZB You, AB Shaik, J Cao, ... Neuropharmacology 158, 107597, 2019 | 70 | 2019 |
| Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug R Rais, KM Lemberg, L Tenora, ML Arwood, A Pal, J Alt, Y Wu, J Lam, ... Science advances 8 (46), eabq5925, 2022 | 62 | 2022 |
| Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma AR Hanaford, J Alt, R Rais, SZ Wang, H Kaur, DLJ Thorek, CG Eberhart, ... Translational oncology 12 (10), 1314-1322, 2019 | 62 | 2019 |
| Still NAAG’ing after all these years: the continuing pursuit of GCPII inhibitors JJ Vornov, KR Hollinger, PF Jackson, KM Wozniak, MH Farah, P Majer, ... Advances in Pharmacology 76, 215-255, 2016 | 59 | 2016 |
| High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice CA Boateng, OM Bakare, J Zhan, AK Banala, C Burzynski, E Pommier, ... Journal of medicinal chemistry 58 (15), 6195-6213, 2015 | 57 | 2015 |
| DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation C Rojas, E Barnaeva, AG Thomas, X Hu, N Southall, J Marugan, ... Scientific reports 8 (1), 17715, 2018 | 50 | 2018 |
Barbara S. SlusherProfessor of Neurology, Psychiatry, Neuroscience, Medicine, Oncology, Johns Hopkins UniversityVerified email at jhmi.edu